MX2018005467A - Composiciones que comprenden vectores lentivirales que expresan interleucina-12, y metodos de uso de las mismas. - Google Patents

Composiciones que comprenden vectores lentivirales que expresan interleucina-12, y metodos de uso de las mismas.

Info

Publication number
MX2018005467A
MX2018005467A MX2018005467A MX2018005467A MX2018005467A MX 2018005467 A MX2018005467 A MX 2018005467A MX 2018005467 A MX2018005467 A MX 2018005467A MX 2018005467 A MX2018005467 A MX 2018005467A MX 2018005467 A MX2018005467 A MX 2018005467A
Authority
MX
Mexico
Prior art keywords
compositions
methods
lentiviral vectors
vectors expressing
cancer
Prior art date
Application number
MX2018005467A
Other languages
English (en)
Inventor
Henrik Ter Meulen Jan
Lars Aksel Berglund Peter
Tina Albershardt Tinglan
Original Assignee
Immune Design Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Design Corp filed Critical Immune Design Corp
Publication of MX2018005467A publication Critical patent/MX2018005467A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15044—Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta solicitud de patente se refiere generalmente al tratamiento del cáncer, y más particularmente al uso de un lentivirus pseudotipificado que expresa IL-12 para el tratamiento del cáncer.
MX2018005467A 2015-11-09 2016-11-08 Composiciones que comprenden vectores lentivirales que expresan interleucina-12, y metodos de uso de las mismas. MX2018005467A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562252877P 2015-11-09 2015-11-09
US201562261655P 2015-12-01 2015-12-01
PCT/US2016/060968 WO2017083291A1 (en) 2015-11-09 2016-11-08 Compositions comprising lentiviral vectors expressing il-12 and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2018005467A true MX2018005467A (es) 2018-12-11

Family

ID=57421942

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005467A MX2018005467A (es) 2015-11-09 2016-11-08 Composiciones que comprenden vectores lentivirales que expresan interleucina-12, y metodos de uso de las mismas.

Country Status (15)

Country Link
US (1) US11365230B2 (es)
EP (2) EP3738973A1 (es)
JP (1) JP2018537432A (es)
KR (1) KR20180073586A (es)
CN (1) CN108350037A (es)
AU (1) AU2016354000A1 (es)
BR (1) BR112018008911A2 (es)
CA (1) CA3003890A1 (es)
EA (1) EA201890861A1 (es)
ES (1) ES2785503T3 (es)
HK (1) HK1254128A1 (es)
IL (1) IL259022A (es)
MX (1) MX2018005467A (es)
SG (1) SG11201803546WA (es)
WO (1) WO2017083291A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI531652B (zh) 2005-12-02 2016-05-01 美國紐約大學西奈山醫學院 表現非原生表面蛋白質之嵌合病毒及其用途
CN111172120A (zh) 2013-03-14 2020-05-19 西奈山伊坎医学院 新城疫病毒及其用途
CN112575036A (zh) 2016-04-22 2021-03-30 深圳市亦诺微医药科技有限公司 I型单纯疱疹病毒载体及重组溶瘤性i型单纯疱疹病毒
CN112513281A (zh) * 2018-07-10 2021-03-16 基因药物株式会社 抗肿瘤组合物
CN110819648B (zh) * 2018-08-07 2022-01-28 北京惠大生物科技有限公司 感染有慢病毒的永生化dc细胞及其在杀伤表达mage-a3肿瘤细胞中的应用
WO2020131656A1 (en) * 2018-12-17 2020-06-25 Immune Design Corp. Pathogen-associated molecular pattern molecules and rna immunogenic compositions and methods of using the compositions for treating cancer

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4569794A (en) 1984-12-05 1986-02-11 Eli Lilly And Company Process for purifying proteins and compounds useful in such process
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
CA1339684C (en) 1988-05-17 1998-02-24 Peter H. Quail Plant ubquitin promoter system
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
TW279133B (es) 1990-12-13 1996-06-21 Elan Med Tech
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5279552A (en) 1993-01-11 1994-01-18 Anton Magnet Intradermal injection device
US5997501A (en) 1993-11-18 1999-12-07 Elan Corporation, Plc Intradermal drug delivery device
US6045802A (en) 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
DK0784483T3 (da) 1994-10-03 2001-03-26 Us Gov Health & Human Serv Præparat indeholdende et rekombinant virus, der udtrykker et antigen, og et rekombinant virus, der udtrykker et immunstimul
US5891680A (en) 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
US5660835A (en) 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US5994104A (en) 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
WO1998032869A1 (en) 1997-01-29 1998-07-30 Neurosearch A/S Expression vectors and methods for in vivo expression of therapeutic polypeptides
EP1062340A2 (en) 1998-03-13 2000-12-27 The Baylor College of Medicine Compositions and methods for the treatment and prevention of metastatic disorders
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
JP4768916B2 (ja) 1998-09-15 2011-09-07 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション サイトカイン発現が遺伝的に増強された抗原提示細胞のインサイチュ注入
US6776776B2 (en) 1999-10-14 2004-08-17 Becton, Dickinson And Company Prefillable intradermal delivery device
US6569143B2 (en) 1999-10-14 2003-05-27 Becton, Dickinson And Company Method of intradermally injecting substances
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
US7241275B2 (en) 1999-10-14 2007-07-10 Becton, Dickinson And Company Intradermal needle
US20020193740A1 (en) 1999-10-14 2002-12-19 Alchas Paul G. Method of intradermally injecting substances
EP1248654B1 (en) 2000-01-20 2005-10-05 Universität Zürich Institut für Medizinische Virologie Intra-tumoral administration of il-12 encoding naked nucleic acid molecules
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
WO2003041763A2 (en) 2001-11-14 2003-05-22 Medical Instill Technologies, Inc. Intradermal delivery device and method
DK1478428T3 (da) 2002-02-04 2009-09-14 Becton Dickinson Co Indretning og fremgangsmåde til aflevering eller udtagning af en substans gennem huden
US7115108B2 (en) 2002-04-02 2006-10-03 Becton, Dickinson And Company Method and device for intradermally delivering a substance
US7047070B2 (en) 2002-04-02 2006-05-16 Becton, Dickinson And Company Valved intradermal delivery device and method of intradermally delivering a substance to a patient
US6780171B2 (en) 2002-04-02 2004-08-24 Becton, Dickinson And Company Intradermal delivery device
CN1708320A (zh) 2002-11-07 2005-12-14 郎基·常 经修饰的树突状细胞
US7108679B2 (en) 2004-03-11 2006-09-19 Becton, Dickinson And Company Intradermal syringe and needle assembly
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US8158413B2 (en) 2005-10-17 2012-04-17 Institut Pasteur Lentiviral vector-based vaccine
DK1989224T3 (da) 2006-02-24 2011-02-14 Us Gov Health & Human Serv Immunogene peptider og anvendelsesmetoder
BRPI0716959A2 (pt) 2006-09-26 2013-10-29 Infectious Disease Res Inst Composição de vacina contendo adjuvante sintético
EP2150618B1 (en) 2007-05-04 2017-10-11 University Health Network Il-12 immunotherapy for cancer
WO2009035528A2 (en) 2007-09-07 2009-03-19 University Of Georgia Research Foundation, Inc. Synthetic lipid a derivative
WO2009076524A2 (en) 2007-12-11 2009-06-18 The University Of North Carolina At Chapel Hill Polypurine tract modified retroviral vectors
WO2010051820A1 (en) 2008-11-10 2010-05-14 Aarhus Universitet Multiplexed cytokine vaccination
WO2010126766A1 (en) * 2009-04-30 2010-11-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
DK2770061T3 (en) 2009-07-24 2019-01-07 Immune Design Corp NON-INTEGRATING LENTIVIRUS VECTORS
CA2842053C (en) 2011-07-27 2018-01-16 Philogen S.P.A. Il-12 immunoconjugate
JP6489353B2 (ja) 2011-10-11 2019-03-27 ウニヴェルズィテート チューリッヒ 腫瘍療法のためのｉｌ−１２とｔ細胞阻害分子遮断薬とを含む医薬組成物
EP2591796A1 (en) 2011-11-10 2013-05-15 Universität Zürich Combination medicament comprising IL-12 and an anti-CTLA-4 ligand for tumor therapy
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
EA038702B1 (ru) * 2012-03-30 2021-10-07 Иммьюн Дизайн Корп. Лентивирусные векторные частицы, имеющие улучшенную эффективность трансдукции клеток, экспрессирующих dc-sign
WO2015066715A1 (en) 2013-11-04 2015-05-07 Viracell Advanced Products, Llc Virus-like particles and methods related thereto
US20160311879A1 (en) 2013-12-18 2016-10-27 Intrexon Corporation Single chain il-12 nucleic acids, polypeptides, and uses thereof
US20170291934A1 (en) 2014-09-22 2017-10-12 Charles C. Reed Improved therapeutic control of heterodimeric and single chain forms of interleukin-12

Also Published As

Publication number Publication date
ES2785503T3 (es) 2020-10-07
EA201890861A1 (ru) 2018-10-31
US20190375811A1 (en) 2019-12-12
CN108350037A (zh) 2018-07-31
BR112018008911A2 (pt) 2018-11-27
US11365230B2 (en) 2022-06-21
CA3003890A1 (en) 2017-05-18
EP3374374A1 (en) 2018-09-19
EP3374374B1 (en) 2020-03-04
IL259022A (en) 2018-06-28
HK1254128A1 (zh) 2019-07-12
JP2018537432A (ja) 2018-12-20
SG11201803546WA (en) 2018-05-30
KR20180073586A (ko) 2018-07-02
EP3738973A1 (en) 2020-11-18
WO2017083291A1 (en) 2017-05-18
AU2016354000A1 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2018005467A (es) Composiciones que comprenden vectores lentivirales que expresan interleucina-12, y metodos de uso de las mismas.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
PH12017502255A1 (en) Nrf2 regulators
EP3800248A3 (en) Crispr-cas-related methods, compositions and components for cancer immunotherapy
MX2017005252A (es) Metodos para la preparacion de ribosidos.
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
GB2541571A (en) Pharmaceutical compositions
PH12019502002A1 (en) Combination theraphy
MX2019001672A (es) Composiciones de poxvirus quiméricos y usos de las mismas.
MX2023004969A (es) Metodos para tratar y prevenir infeccion por c. difficile.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2018000395A (es) Proteinas y composiciones inmunizantes que contienen proteinas de klebsiella y metodos de uso.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
WO2015123449A3 (en) Compositions and methods of using microrna inhibitors
MX370412B (es) Compuesto antimicotico.
MX2017012553A (es) Compuestos espirociclicos.
SG11202108852PA (en) Hair treatment composition
MX359029B (es) Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -.
IL288937A (en) Improved treatment using eyp001
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2019003755A (es) Regimen de dosificacion de avelumab para el tratamiento de cancer.